[CAS NO. 315706-13-9] 4EGI-1
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [315706-13-9]
Store
Catalog
SLK-S7369
Brand
Selleck
CAS
315706-13-9
DESCRIPTION [315706-13-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 451.28 |
| Molecular Formula | C18H12Cl2N4O4S |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2159 mL | 11.0796 mL | 22.1592 mL |
| 5 mM | 0.4432 mL | 2.2159 mL | 4.4318 mL |
| 10 mM | 0.2216 mL | 1.1080 mL | 2.2159 mL |
| 50 mM | 0.0443 mL | 0.2216 mL | 0.4432 mL |
Description
4EGI-1 is a competitive interaction inhibitor by binding to eIF4E with of 25 μM. 4EGI-1 specifically inhibits the function of by blocking the activation of . 4EGI-1 induces .
In vitro
4EGI-1 disrupts the eIF4F complex and inhibits Cap-dependent translation in vitro. 4EGI-1 has proapoptotic activity in Jurkat cells, and potently inhibits cell growth with IC50 of approximately 6 μM in A549 lung cancer cells. 4EGI-1 augments TRAIL-induced apoptosis through induction of DR5 and down-regulation of c-FLIP, independent of inhibition of cap-dependent protein translation in human lung cancer cells. In addition, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.